45d agoSeeking AlphaBULLISH 58Analyst
uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade)
uniQure upgraded to speculative Buy as FDA aligns on BLA path for Huntington’s gene therapy. Click for more on QURE stock.
Archived explainer. For the current picture see today's QURE page.
Why Is UNIQURE N V (QURE) Stock Up Today?
By the Top Tier Newswire AI Desk · September 30, 2026 at 9:55 AM ET · reviewed against 29 wire stories
UNIQURE N V (QURE) is up +5.00% in the latest session. Our newswire has captured 29 stories on QURE across 15 sources in the last 36 hours, with AI sentiment reading bearish (avg 41/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why QURE stock is up today
uniQURE N.V. (QURE) shares rose 5.00% to $25.74 in the current session after a period of significant volatility. The recent four-year data from its AMT-130 Huntington’s disease trial triggered a sharp selloff earlier in the week, but the stock has since rebounded amid a mix of upgraded analyst ratings and a reaffirmed regulatory path for FDA approval.
What Happened
The stock’s recent selloff was driven by weaker-than-expected four-year data from uniQure’s AMT-130 trial, which showed a smaller benefit compared to the three-year result. This led to a price target cut from Goldman Sachs and a broader sell-off. However, the company clarified that the three-year data remains robust and the FDA has signaled openness to reviewing its BLA for AMT-130. This regulatory alignment prompted a rating upgrade to speculative Buy from Seeking Alpha, which helped reverse the downward momentum.
Analysts at RBC and Wells Fargo have also weighed in, with RBC calling the stock reaction "overdone" and Wells Fargo identifying the weakness as an attractive entry point. These developments, combined with a broader market environment that saw health care stocks move in Tuesday’s session, contributed to the current upward trend.
What The Data Shows
QURE opened the session at $24.47 and reached an intraday high of $26.68 at 9:45 AM ET before settling near $25.82. The stock is trading on 0.9 million shares so far, which is 0.5 times the 3-month daily average. Over the past 8 sessions, the stock has fallen 44.1% from $44.00 to $24.59. In the last 90 days, insiders have sold a total of $3.3 million in shares, with the most recent filing on July 7, 2026. Options activity has also been skewed toward puts, with the largest single print at $203,000.
What To Watch
The company is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any further developments on the AMT-130 BLA timeline.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
QURE by the numbers
Last: $25.74Session: +5.00%7 sessions: -45.48%Coverage: 29 stories / 15 sourcesAI sentiment: 41/100 (bearish)Mkt cap: $2.7B52w: $8.73 to $71.50
The headlines behind the move
46d agoThe FlyBEARISH 34Analyst
uniQure price target lowered to $31 from $46 at Goldman Sachs
46d agoPR NewswireBEARISH 28General
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violations. NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Shares of uniQure N.V....
46d agoStocktwits NewsBEARISH 32Product/PR
QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years.
46d agoThe FlyBULLISH 56Analyst
uniQure weakness creates attractive opportunity, says Wells Fargo
46d agoThe FlyBEARISH 42Analyst
RBC says uniQure’s four-year HD data mixed, stock reaction ‘overdone’
46d agoSeeking AlphaBULLISH 56Analyst
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish
uniQure's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review. Click to read more about the Buy rating for QURE.
46d agoSeeking AlphaBULLISH 63Product/PR
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing - Slideshow
2026-09-29. The following slide deck was published by uniQure N.V.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on QURE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier QURE move explainers: 2026-11-02 · 2026-09-30 · 2026-09-29 · 2026-08-25